Novoseven

Get a Price/Quote

MOQ : 50 Boxes

Novoseven Specification

Molecular Formula
C7699H11999N2105O2183S54

Application
Hospital, Clinical

CAS No
9001-94-7

Purity
>98%

Grade
Pharmaceutical Grade

Formulations Type
Injectables

Formulations Form
Liquid

Treatments & Functions
For treatment and prevention of bleeding in hemophilia and other congenital factor VII deficiency

Gender/Age Group
Suitable For All Ages

Dosage Guidelines
As directed by physician

Volume
1 mg / 2 mg / 5 mg / 8 mg per vial

Storage Instructions
Store in Cool

Novoseven Trade Information

Minimum Order Quantity
50 Boxes

FOB Port
Mundra Port

Supply Ability
1000 Boxes Box Per Month

Delivery Time
30 Days

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
As Per buyer Requirements

Main Export Market(s)
North America, South America, Eastern Europe, Western Europe, Middle East, Africa, Central America, Asia, Australia

Main Domestic Market
All India

Certifications
ISO, GMP, WHO, FDA

About Novoseven

Novoseven

Product Description

We are one of the leading exporter, supplier, distributor, wholesaler, trader and importers of a wide range of Novoseven 1mg and 2mg that are formulated by using safe and pure ingredients. These Novoseven 1mg and 2mg is made available in various packaging options to suit the varied demands and specifications of the clients.

Specification:

Generic Name: Eptacog Alfa(activated)
Packing: Vial
Brand Name: Abbott

Effective Bleeding Control

Novoseven works by rapidly activating the bodys natural clotting mechanisms. Eptacog alfa (activated) effectively addresses bleeding episodes in individuals with hemophilia or factor VII deficiency, reducing hospitalization times and improving patient outcomes significantly. It is suitable for all age groups and is used across hospital and clinical settings.

Reliable and Convenient Packaging

The product is supplied in vials of various concentrations, each accompanied by a solvent to ensure proper reconstitution before intravenous administration. Its packaging supports medical professionals with precise dosing in critical situations, allowing for reliable access to safe, ready-to-use medication.

FAQs of Novoseven:

Q: How is Novoseven administered to patients?

A: Novoseven is given by intravenous injection under the supervision of a healthcare professional, usually in a hospital or clinical setting, to ensure safety and efficacy during administration.

Q: What conditions does Novoseven treat?

A: Novoseven is indicated for the treatment and prevention of bleeding in patients with hemophilia A or B with inhibitors, congenital factor VII deficiency, and acquired hemophilia.

Q: When should Novoseven be used?

A: Novoseven should be used as soon as bleeding episodes occur or as prescribed by a physician for ongoing management. Timely administration can help prevent complications related to uncontrolled bleeding.

Q: Where should Novoseven be stored for optimal results?

A: Novoseven must be stored in a cool environment to maintain stability and efficacy. Adhering to the manufacturers storage guidelines ensures the product remains effective until its expiration date.

Q: What is the process for preparing Novoseven before administration?

A: Novoseven is supplied as a liquid in a vial accompanied by a solvent. Preparation involves careful reconstitution and dosing by medical personnel, following specific guidelines to guarantee safety and accuracy.

Q: How does Novoseven benefit patients with hemophilia?

A: Novoseven helps restore normal blood clotting function, effectively controlling and preventing bleeding episodes in patients who have clotting disorder and inhibitors, resulting in better quality of life and reduced need for additional interventions.

Tell us about your requirement